Our goal is to meaningfully improve people’s lives by learning from the wisdom of their adaptive immune systems. It’s a bold objective that we’re uniquely built to achieve.
-
Every immune system has a story to tell.The key is knowing how to listen.At Adaptive, we’re writing the next chapter of precision health — powered by immune-driven medicine. -
Adaptive and Genentech, a member of the Roche Group, partner on the next generation of cell therapyLearn moreRead our press release
*The completion of the agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to occur in the first quarter of 2019.
-
Medicare now covers the FDA-cleared clonoSEQ® Assay for patients with multiple myeloma and B-cell ALL
Coverage available for testing performed on bone marrow samples at time points throughout a patient’s treatmentLearn moreRead our press releaseclonoSEQ is an FDA-cleared in vitro diagnostic (IVD) test service for use in B-cell ALL and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service. clonoSEQ is available by prescription only. For important information about the FDA-cleared uses of clonoSEQ, including test limitations, visit clonoSEQ.com/technical-summary.
Keep up to date with Adaptive.